Aspen Aerogels (NYSE:ASPN) Stock, Quote.Headers.trade-ideas

Aspen Aerogels

Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ASPN

UAMY

Top 3 Materials Stocks That May Collapse In Q3

movers image

Movers

APPS

BMBL

BROS

CDLX

COEP

FLNC

FROG

FSLY

GNLN

LUXH

PGEN

SEZL

STAF

VIRX

WENA

XPON

Why Digital Turbine Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Earnings

Small Cap

Analyst Ratings

Vulcan Materials Company (NYSE: VMC) is scheduled to release second-quarter 2024 results on Aug 6, before the opening bell.

Vulcan to Report Q2 Earnings: What&#39;s in the Offing?

Aspen Aerogels Inc

Roth MKM analyst Chip Moore reiterates Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and maintains $36 price target.

Price Target

Reiteration

Roth MKM Reiterates Buy on Aspen Aerogels, Maintains $36 Price Target

TD Cowen analyst Jeffrey Osborne maintains Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and raises the price target from $36 to $41.

TD Cowen Maintains Buy on Aspen Aerogels, Raises Price Target to $41

Excluding New Georgia Facility From Collateral Structure

Aspen Aerogels Secures $125M Term Loan And $100M Revolving Credit Facility With MidCap Financial To Redeem Convertible Note And Support Plant II Financing

As of Aug 19, 2024, three stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Aspen Aerogels Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>)</h3>
<ul>
<li>On Aug. 7, Aspen Aerogels reported better-than-expected second-quarter revenue results. &#8220;This quarter&#8217;s results demonstrate the significant operating leverage of our business model as we continue to utilize a higher percentage of our current capacity and effectively execute our strategy,&#8221; commented Don Young, Aspen&#8217;s President and CEO. The company's stock gained around 35% over the past five days and has a <a href="https://www.benzinga.com/quote/ASPN">52-week high of $31.74</a>.</li>
<li>RSI Value: 73.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ASPN Price Action: Shares of Aspen Aerogels gained 22.6% to close at $29.92 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Anglogold Ashanti PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>)</h3>
<ul>
<li>On Aug. 6, AngloGold Ashanti reported a year-over-year increase in H1 financial results. &#8220;These results show the hard work that&#8217;s been done to improve the fundamentals of our business, to drive productivity benefits and manage costs to ensure we capture the benefit of stronger gold prices,&#8221; CEO Alberto Calderon said. &#8220;We expect to deliver an even stronger second-half performance.&#8221; The company's stock gained around 12% over the past month and <a href="https://www.benzinga.com/quote/AU">has a 52-week high</a> of $31.65.</li>
<li>RSI Value: 70.53</li>
<li>AU Price Action: Shares of Anglogold Ashanti gained 3.6% to close at $31.47 on Friday.</li>
</ul>
<h3 class="wp-block-heading">United States Antimony Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#NYSE">UAMY</a>)</h3>
<ul>
<li>On Aug. 9, the company said revenues for the first six months of 2024 increased 26%, or $1.169 million, to $5.6 million, compared to the first six months of 2023. The company's stock gained around 71% over the past month and has a <a href="https://www.benzinga.com/quote/UAMY">52-week high</a> of $0.57.</li>
<li>RSI Value: 84.97</li>
<li>UAMY Price Action: Shares of United States Antimony gained 11.6% to close at $0.53 on Friday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40420521/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></li>
</ul>

HC Wainwright &amp; Co. analyst Amit Dayal maintains Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and raises the price target from $25 to $30.

HC Wainwright & Co. Maintains Buy on Aspen Aerogels, Raises Price Target to $30

Benchmark analyst Subash Chandra reiterates Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and maintains $14 price target.

Benchmark Reiterates Buy on Aspen Aerogels, Maintains $14 Price Target

WIIM

Aspen Aerogels shares are trading higher after the company reported better-than-expected Q2 revenue results.

Shares of Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/08/40244718/digital-turbine-q1-results-exceed-estimates-sees-continued-demand-in-h2-fy25">quarterly financial results.</a>
Revenue declined 19% Y/Y to $118.0 million, beating the consensus of $116.03 million. Adjusted EPS stood at 7 cents, surpassing the consensus of 4 cents.
Digital Turbine shares jumped 20.8% to $2.15 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) rose 36.5% to $0.1140 in today's pre-market trading. Expion360 shares dipped 68% on Wednesday after the company priced a $10 million underwritten public offering.</li>
<li>Anew Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WENA#NASDAQ">WENA</a>) gained 25% to $1.360 in pre-market trading. Anew Medical announced the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for neurodegenerative diseases to include Alzheimer&#8217;s disease, Parkinson&#8217;s diseases, and amyotrophic lateral sclerosis.</li>
<li>Luxurban Hotels Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) gained 26.3% to $0.12 in pre-market trading after falling 11% on Wednesday.</li>
<li>Coeptis Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) jumped 24.8% to $0.26 in pre-market trading.</li>
<li>Aspen Aerogels Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) shares gained 21% to $22.38 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) gained 18% to $93.02 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares gained 17.3% to $0.5725 in pre-market trading after surging 39% on Wednesday.</li>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) gained 13.7% to $15.73 in pre-market trading after the company reported better-than-expected third-quarter revenue results..</li>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares rose 11.4% to $1.56 in pre-market trading after declining 8% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cardlytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) shares dipped 49.6% to $3.48 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>Outset Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) shares declined 47.1% to $1.80 in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY24 revenue guidance.</li>
<li>Bumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) shares declined 39.8% to $4.85 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>Viracta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) declined 38.9% to $0.2744 in pre-market trading.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares fell 36.1% to $2.59 in pre-market trading after jumping 58% on Wednesday.</li>
<li>JFrog Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) fell 27.4% to $24.73 pre-market trading after the company reported worse-than-expected second-quarter revenue results. Additionally, the company issued FY24 guidance below estimates.</li>
<li>Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) fell 21.5% to $0.22 in today's pre-market trading after the company priced its $3.445 million public offering of 13.25m units at $0.26 per unit.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares fell 20.7% to $29.89 in pre-market trading after the company reported second-quarter results.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) fell 20.5% to $5.42 in pre-market trading after the company issued FY24 and Q3 guidance below estimates.</li>
<li>Precigen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) shares fell 18.1% to $0.9660 in pre-market trading after the company priced $30 million public offering of 35,294,118 common stock at $0.85/share.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/news/24/08/40218858/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40218858/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Guidance

Aspen Aerogels Sees FY24 Revenue ~$390M Vs $395M Estimate

Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.05 by 40 percent. The company reported quarterly sales of $117.800 million which beat the analyst consensus estimate of $101.200 million by 16.40 percent. This is a 144.61 percent increase over sales of $48.158 million the same period last year.

Earnings Beats

Earnings Misses

Aspen Aerogels Q2 2024 Adj. EPS $0.03 Misses $0.05 Estimate, Sales $117.800M Beat $101.200M Estimate

Barclays initiates coverage on Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Overweight rating and announces Price Target of $27.

Initiation

Barclays Initiates Coverage On Aspen Aerogels with Overweight Rating, Announces Price Target of $27

Aspen Aerogels's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) short percent of float has fallen 17.59% since its last report. The company recently reported that it has 3.70 million shares sold short, which is 6.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Aspen Aerogels Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1719236712_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Aspen Aerogels has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Aspen Aerogels's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Aspen Aerogels's peer group average for short interest as a percentage of float is 3.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

(ASPN) - Analyzing Aspen Aerogels's Short Interest

12 analysts have expressed a variety of opinions on Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $31.33, a high estimate of $38.00, and a low estimate of $22.00. This current average reflects an increase of 22.48% from the previous average price target of $25.58. 
<img src="https://www.benzinga.com/files/images/story/2024/1718377250_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Aspen Aerogels by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Stine</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Tom Curran</td>
<td>Seaport Global</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Chip Moore</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jeffrey Osborne</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Christopher Souther</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Chip Moore</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Amit Dayal</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Chip Moore</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Aspen Aerogels. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Aspen Aerogels compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Aspen Aerogels's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Aspen Aerogels's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ASPN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Aspen Aerogels analyst ratings.</a>
<h2>Unveiling the Story Behind Aspen Aerogels</h2>
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.
<h3>Key Indicators: Aspen Aerogels's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Aspen Aerogels's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 107.3%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Aspen Aerogels's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Aspen Aerogels's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.37%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Aspen Aerogels's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.26%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.29.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 12 Analyst Ratings Have To Say About Aspen Aerogels

Craig-Hallum analyst Eric Stine maintains Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and raises the price target from $33 to $38.

Craig-Hallum Maintains Buy on Aspen Aerogels, Raises Price Target to $38

Seaport Global analyst Tom Curran maintains Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and raises the price target from $31 to $38.

Seaport Global Maintains Buy on Aspen Aerogels, Raises Price Target to $38

Aspen Aerogel Announces Design Award From Valmet Automotive To Supply The Porsche 718 Series; Co. Reiterates 2024 Financial Outlook

Roth MKM analyst Chip Moore reiterates Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and raises the price target from $28 to $36.

Roth MKM Reiterates Buy on Aspen Aerogels, Raises Price Target to $36

TD Cowen analyst Jeffrey Osborne maintains Aspen Aerogels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) with a Buy and raises the price target from $30 to $36.

TD Cowen Maintains Buy on Aspen Aerogels, Raises Price Target to $36

U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Wednesday.
Shares of Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) rose sharply during Wednesday's session following better-than-expected <a href="https://www.benzinga.com/news/24/06/39183754/ollies-surges-on-strong-q1-earnings-raises-financial-outlook-amid-consumer-bargain-hunting">first-quarter earnings</a>.
The company reported first-quarter FY24 sales growth of 10.8% year-on-year to $508.82 million, beating the analyst consensus estimate of $505.79 million. Adjusted EPS of 73 cents beat the analyst consensus estimate of 65 cents, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Ollie's raised FY24 adjusted EPS outlook from $3.10 – $3.20 to $3.18 – $3.28, against the consensus of $3.19. The company raised FY24 sales outlook from $2.248 billion – $2.273 billion to $2.257 billion – $2.277 billion,&nbsp; versus the Street view of $2.27 billion.
Ollie&#8217;s Bargain Outlet shares climbed 7.8% to $88.43 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>WalkMe Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKME#NASDAQ">WKME</a>) shares jumped 42.1% to $13.70 after the company announced it entered into a definitive agreement to be acquired by SAP.</li>
<li>Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) gained 34.9% to $3.6010 following better-than-expected third-quarter financial results.</li>
<li>Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) shares climbed 16.4% to $12.31 after the company announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) shares jumped 16% to $4.030 after the company received a multi-year purchase agreement with an estimated value of around a quarter-billion dollars.</li>
<li>Verint Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) surged 15.3% to $32.54 after the company reported better-than-expected first-quarter financial results and issued strong FY25 guidance.</li>
<li>Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) shares gained 15.1% to $20.26 as the company reported better-than-expected second-quarter financial results.</li>
<li>Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) climbed 15% to $124.20 after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>United Natural Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) shares rose 12.7% to $13.69 following upbeat quarterly earnings.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) gained 10.5% to $6.84. agilon health named Jeff Schwaneke as new Chief Financial Officer.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) rose 10.2% to $29.26. It was reported Tuesday that Massachusetts securities regulators are probing retail investor Keith Gill.</li>
<li>CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) climbed 10.4% to $4.46.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 10.2% to $19.57.</li>
<li>Axcelis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) shares rose 8.8% to $121.12</li>
<li>Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) gained 7.7% to $50.63. Guggenheim analyst Subbu Nambi initiated coverage on Twist Bioscience with a Buy rating, while announcing a price target of $53.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) rose 6.8% to $78.68.</li>
<li>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) gained 6.4% to $1,011.48 following a report suggesting the company will ship its chipmaking machine to Taiwan Semiconductor Manufacturing.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) rose 6.1% to $22.58.</li>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) rose 5.7% to $30.68. Piper Sandler analyst Alexander Potter maintained Aspen Aerogels with an Overweight and raised the price target from $30 to $36.</li>
<li>Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) gained 5.5% to $160.79.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) gained 5.3% to $321.78 as the company reported better-than-expected financial results for the first quarter of fiscal 2025 and raised guidance for fiscal-year 2025 on Tuesday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39183037/keurig-dr-pepper-to-rally-around-18-here-are-10-top-analyst-forecasts-for-wednesday">Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday</a>

Intraday Update

ACLS

ASML

CRWD

CVAC

GWRE

MMYT

NVAX

OLLI

SFIX

TWST

UNFI

VRNT

WKME

Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday

Oppenheimer analyst Colin Rusch maintained a Buy rating on Aspen Aerogels (ASPN – Research Report) today and set a price target of $32.00. The comp...

Oppenheimer Sticks to Their Buy Rating for Aspen Aerogels (ASPN)

In a report released today, Eric Stine from Craig-Hallum assigned a Buy rating to Aspen Aerogels (ASPN – Research Report). The company's shares clo...

Aspen Aerogels (ASPN) Gets a Buy from Craig-Hallum

Analyst Jeff Osborne from TD Cowen maintained a Buy rating on Aspen Aerogels (ASPN – Research Report) and increased the price target to $41.00 from...

Strategic Financial Moves and Robust Performance Solidify Buy Rating for Aspen Aerogels

In a report released today, Chip Moore from Roth MKM reiterated a Buy rating on Aspen Aerogels (ASPN – Research Report), with a price target of $36...

Roth MKM Sticks to Its Buy Rating for Aspen Aerogels (ASPN)

In a report released today, Eric Stine from Craig-Hallum maintained a Buy rating on Aspen Aerogels (ASPN – Research Report). The company's shares c...

Craig-Hallum Remains a Buy on Aspen Aerogels (ASPN)

Aspen Aerogels (ASPN) has provided an update. Aspen Aerogels, Inc. has solidified its leadership by renewing President and CEO Donald R. Young's co...

Aspen Aerogels CEO Contract Renewed Through 2027

Analyst Jeff Osborne from TD Cowen maintained a Buy rating on Aspen Aerogels (ASPN – Research Report) and keeping the price target at $41.00. Jeff ...

Aspen Aerogels: A Buy Rating Amidst EV Market Potential and Proactive Risk Management

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Aspen Aerogels

Aspen Aerogels (ASPN) Forecast

Aspen Aerogels (NYSE:ASPN) Stock, Quote.Headers.trade-ideas